Cardiology

Pharmalot

Pharmalittle: Hospitals criticize feds over remdesivir supplies; Moderna starting mid-stage Covid-19 vaccine trials soon

By Ed Silverman

Health

Giving blood thinners to severely ill Covid-19 patients is gaining ground

By Elizabeth Cooney

Health Tech

Taking a page from Apple, Fitbit launches a sweeping heart study

By Erin Brodwin

Health Tech

In fading steel towns, chronically ill patients hope video visits stay after the pandemic goes

By Casey Ross

Health

‘Where are all our patients?’: Covid phobia is keeping people with serious heart symptoms away from ERs

By Usha Lee McFarling

Health

Blood clots in severe Covid-19 patients leave clinicians with clues about the illness — but no proven treatments

By Elizabeth Cooney

In the Lab

MIT’s Koch Institute wins STAT Madness with technology to see tiny ovarian tumors

By Elizabeth Cooney

Health

New drug from Merck, Bayer reduces hospitalizations for heart failure patients

By Matthew Herper

Health Tech

The coronavirus is imperiling drug studies. A virtual study of the Apple Watch could be positioned to thrive

By Rebecca Robbins

Health

Her son died. Two decades later, she met the medical student who got his heart

By Karen Weintraub

Pharma

Heart association admits ‘misstep’ in its drug-store aspirin displays with Bayer

By Phil Galewitz — Kaiser Health News

Health Tech

AI has arrived in medical imaging. Now the FDA needs to monitor its impact on patients

By Casey Ross

Biotech

After 21-year journey, Esperion to test market for a cholesterol pill that is less expensive than some competitors

By Matthew Herper

Health

How the psychology of a $4.99 price tag might influence who undergoes heart surgery

By Eric Boodman

Health

FDA approves AI-based software that helps doctors take ultrasound pictures of the heart

By Matthew Herper

Pharmalot

Years later, raw clinical trial data tells us the extent of Avandia’s heart risks

By Ed Silverman

Health

‘Donation after cardiac death’: New heart transplant method being tested for the first time in the U.S.

By Shraddha Chakradhar

Biotech

Regeneron’s Yancopoulos is still bitter over Praluent sales. Can Novartis do better?

By Adam Feuerstein

Biotech

AstraZeneca fish oil drug fails, leaving Amarin as last drug standing

By Matthew Herper

Health Tech

At Mayo Clinic, AI engineers face an ‘acid test’: Will their algorithms help real patients?

By Casey Ross

Biotech

FDA approves Amarin fish-oil-derived drug to prevent heart attacks and strokes

By Matthew Herper

Biotech

With $9.7 billion acquisition, Novartis bets that heart drugs are coming back

By Matthew Herper

Biotech

Amarin releases interim EVAPORATE data — and mineral oil makes another appearance

By Chris Morrison

Health

Big study casts doubt on need for many heart procedures

By Associated Press

Health

Apple launches virtual health studies aiming to enroll hundreds of thousands of customers

By Rebecca Robbins

In its first tough test, CRISPR base editing slashes cholesterol levels in monkeys

Scientists 3D-map the ‘little brain of the (rat) heart’

Fueled by the Covid-19 pandemic, remote heart monitoring could become tech’s next big target

Pharmalittle: Hackers linked to Iran sought Gilead Covid-19 data; NIH to test remdesivir with a Lilly drug

Pharmalittle: Hospitals criticize feds over remdesivir supplies; Moderna starting mid-stage Covid-19 vaccine trials soon

Giving blood thinners to severely ill Covid-19 patients is gaining ground

Taking a page from Apple, Fitbit launches a sweeping heart study

In fading steel towns, chronically ill patients hope video visits stay after the pandemic goes

‘Where are all our patients?’: Covid phobia is keeping people with serious heart symptoms away from ERs

Blood clots in severe Covid-19 patients leave clinicians with clues about the illness — but no proven treatments

MIT’s Koch Institute wins STAT Madness with technology to see tiny ovarian tumors

New drug from Merck, Bayer reduces hospitalizations for heart failure patients

The coronavirus is imperiling drug studies. A virtual study of the Apple Watch could be positioned to thrive

Her son died. Two decades later, she met the medical student who got his heart

Heart association admits ‘misstep’ in its drug-store aspirin displays with Bayer

AI has arrived in medical imaging. Now the FDA needs to monitor its impact on patients

After 21-year journey, Esperion to test market for a cholesterol pill that is less expensive than some competitors

How the psychology of a $4.99 price tag might influence who undergoes heart surgery

FDA approves AI-based software that helps doctors take ultrasound pictures of the heart

Years later, raw clinical trial data tells us the extent of Avandia’s heart risks

‘Donation after cardiac death’: New heart transplant method being tested for the first time in the U.S.

Regeneron’s Yancopoulos is still bitter over Praluent sales. Can Novartis do better?

AstraZeneca fish oil drug fails, leaving Amarin as last drug standing

At Mayo Clinic, AI engineers face an ‘acid test’: Will their algorithms help real patients?

FDA approves Amarin fish-oil-derived drug to prevent heart attacks and strokes

With $9.7 billion acquisition, Novartis bets that heart drugs are coming back

Amarin releases interim EVAPORATE data — and mineral oil makes another appearance

Big study casts doubt on need for many heart procedures

Apple launches virtual health studies aiming to enroll hundreds of thousands of customers